Tilray Brands has been expanding while also making progress on its bottom line. If you're an investor who is bullish on the prospects for marijuana in the long term, then odds are, you're familiar with both Tilray Brands (TLRY 4.48%) and Canopy Growth (CGC 7.17%). These companies are both based in Canada and have been eyeing opportunities in the U.S. cannabis market -- if and when it eventually it opens up due to federal legalization. But they have taken very different approaches in their strategies in rece ...

Newsflash: When marijuana is legalized, Americans will buy marijuana legally. Canopy Growth (CGC 1.89%) stock inched 3.2% higher through 10:35 a.m. ET Monday after marijuana news source Marijuana Moment reported on a new positive development for the (legalized) marijuana industry: According to cannabis telehealth platform NuggMD, most Americans now prefer to buy their weed from legal sources. The legal marijuana market There are caveats to this conclusion. As Marijuana Moment describes, NuggMD's survey focu ...

Key Takeaways Canopy Growth Corporation shares dropped Friday after reporting worse-than-expected earnings. Revenues came in 13% lower than a year earlier and net loss widened substantially. Canadian adult-use cannabis sales for the company decreased, offset by an increase in medical cannabis sales Canopy Growth Corporation (CGC) shares dropped Friday after the company's first-quarter fiscal 2025 earnings fell significantly short of expectations. The cannabis producer's revenue of 66.2 million Canadian doll ...

Canopy Growth (NASDAQ:CGC) is among the top Canada-based cannabis producers that investors are watching for clues on how the overall legal marijuana market is performing. Today's decline of more than 8% in CGC stock suggests continued weakness may be forthcoming. The cannabis producer reported revenue for the 2025 fiscal year of $75.8 million, which was down significantly from last year's total of more than $88 million. Even worse, Canopy reported that its net loss ballooned to $127.1 million, or $1.60 per ...

Canopy Growth Corporation. (NASDAQ:CGC) Q1 2025 Earnings Conference Call August 9, 2024 10:00 AM ET Company Participants Tyler Burns - Director, IR David Klein - CEO Judy Hong - CFO Conference Call Participants Aaron Grey - Alliance Global Partners Frederico Gomes - ATB Capital Markets Michael Lavery - Piper Sandler William Kirk - Roth Capital Partners Operator Good morning. My name is Joelle [ph]. I will be your conference operator today. I would like to welcome you to Canopy Growth's First Quarter Fiscal ...

Canopy Growth Corporation (CGC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -19.35%. A quarter ago, it was expected that this company would post a loss of $0.33 per share when it actually produced a loss of $0.28, delivering a surprise of 15.15%. Over the last four quarters, the company ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

ANOPY GROWTH REPORTS FIRST SCAL 2025 FINANCIAL RESULTS Exhibit 99.1 Canopy Growth Reports First Quarter Fiscal Year 2025 Financial Results Focus on profitable revenue generation delivered 67% increase in gross profit year-over-year Record quarter for Canada Medical Cannabis with Net Revenue increasing 20% year-over-year and 6th consecutive quarter of growth Extended maturity of senior secured term loan to December 18, 2026 with an option to further extend to September 18, 2027 SMITHS FALLS, ON, August 9, 20 ...

Focus on profitable revenue generation delivered 67% increase in gross profit year-over-year 1 Adjusted EBITDA is a non-GAAP measure. See "Non-GAAP Measures" and Schedule 5 for a reconciliation of net loss to Adjusted EBITDA. 2Based on internal estimates including sales in both B2B and B2C channels; in local currency 3 Adjusted gross margin is a non-GAAP measure, and for Q1 FY2025 excludes $nil of restructuring cost recorded in cost of goods sold (Q1 FY2024 - excludes $nil of restructuring costs recorded in ...

Financial Reporting and Currency - The company's financial statements are reported in thousands of Canadian dollars, with the majority of operations conducted in Canadian dollars[98] - A hypothetical 10% change in the U.S. dollar against the Canadian dollar would affect the carrying value of net assets by approximately $75.5 million, while a 10% change in the euro would affect it by approximately $20.1 million[161] - The company's cash and cash equivalents, and short-term investments consisted of $75.5 million in interest rate sensitive instruments as of June 30, 2024[162] U.S. Market Expansion and Acquisitions - The company is focusing on accelerating entry into the U.S. cannabis market through the creation of Canopy USA, LLC, with expectations for growth in the U.S. cannabis sector[99] - Canopy USA was created to hold U.S. cannabis investments, with the company modifying its structure to comply with Nasdaq listing requirements, including deconsolidating Canopy USA's financial results[106] - Canopy USA completed the acquisition of Wana, a leading cannabis edibles brand in North America, and Jetty, a California-based producer of cannabis extracts, in 2024[107] - Canopy USA exercised the option to acquire approximately 70% of Acreage's shares, a leading vertically-integrated multi-state cannabis operator in the U.S., on June 4, 2024[107] - Canopy USA holds a 63.5% interest in TerrAscend, a major North American cannabis operator, through exchangeable shares, options, and warrants[108] - Canopy USA holds 60,955,929 common shares issued to Wana shareholders, representing a significant portion of Canopy USA's issued and outstanding shares[109] - Canopy USA issued 60,955,929 common shares and Canopy Growth issued 1,086,279 common shares to Wana shareholders as part of the Wana Amending Agreement[109] - Canopy USA's acquisition of Acreage involves issuing 0.045 of a Canopy Growth common share for each Floating Share held, with a total value of US$30.4 million in common shares issued to Holders[111] - Canopy Growth deconsolidated Canopy USA's financial results as of April 30, 2024, recognizing an equity method investment and a loan receivable at fair value[114] Financial Performance and Metrics - Net revenue for Q1 fiscal 2025 was $66.2 million, a decrease of $10.0 million (13%) compared to $76.3 million in Q1 fiscal 2024[118][120] - Gross margin percentage increased to 35% in Q1 fiscal 2025, up from 18% in Q1 fiscal 2024, representing a 1,700 basis points improvement[118][125] - Net loss from continuing operations was $129.2 million in Q1 fiscal 2025, compared to $10.6 million in Q1 fiscal 2024, a 1,122% increase[118] - Canadian adult-use cannabis revenue decreased by $5.4 million (22%) to $18.9 million in Q1 fiscal 2025, while medical cannabis revenue increased by $3.2 million (20%) to $18.8 million[119][121] - International markets cannabis revenue remained flat at $10.1 million in Q1 fiscal 2025, with growth in Europe offset by declines in Australia[122] - Storz & Bickel revenue increased by $0.4 million (2%) to $18.5 million in Q1 fiscal 2025, driven by strong growth of the Mighty vaporizer and new product launches[123] - This Works revenue was $nil in Q1 fiscal 2025 following the divestiture of the business on December 18, 2023[124] - Cost of goods sold decreased by $19.3 million (31%) to $43.2 million in Q1 fiscal 2025, contributing to the improved gross margin[125] - Canada cannabis segment gross margin increased to $12.1 million (32% of net revenue) in Q1 2025, compared to $(0.3) million (-1% of net revenue) in Q1 2024, driven by cost savings and strong medical cannabis sales[126][127] - International markets cannabis segment gross margin rose to $3.6 million (36% of net revenue) in Q1 2025, up from $3.5 million (34% of net revenue) in Q1 2024, due to higher-margin sales in Poland and lower operational costs[126][127] - Storz & Bickel segment gross margin decreased to $7.3 million (40% of net revenue) in Q1 2025, down from $7.7 million (43% of net revenue) in Q1 2024, primarily due to product mix changes and rebates for discontinued products[126][127] - This Works segment reported no gross margin in Q1 2025 following its divestiture on December 18, 2023, compared to $2.9 million (48% of net revenue) in Q1 2024[126][127] - Total operating expenses decreased by 24% to $52.1 million in Q1 2025, down from $68.4 million in Q1 2024, driven by cost savings and restructuring efforts[128] - General and administrative expenses decreased by 26% to $18.9 million in Q1 2025, compared to $25.5 million in Q1 2024, due to the divestiture of This Works and restructuring actions[128] - Sales and marketing expenses decreased by 27% to $15.2 million in Q1 2025, down from $20.8 million in Q1 2024, reflecting the impact of divestiture and cost-saving initiatives[128] - Share-based compensation expense increased by 12% to $4.2 million in Q1 2025, up from $3.7 million in Q1 2024, due to new grants of restricted share units and options[128][131] - Other income (expense), net, was an expense of $93.9 million in Q1 2025, compared to an income of $46.1 million in Q1 2024, primarily due to non-cash fair value changes in financial assets[132][133] - Loss on asset impairment and restructuring decreased to $0.02 million in Q1 2025, down from $1.9 million in Q1 2024, reflecting reduced restructuring costs and facility closures[131] - Decrease in income of $76.0 million related to non-cash fair value changes on equity method investments, driven by the fair value change of Canopy USA equity method investment[134] - Decrease in non-cash income of $33.5 million related to fair value changes on acquisition-related contingent consideration, primarily due to various acquisition-related contingent consideration[135] - Change of $27.4 million related to charges associated with the settlement of debt, including a gain of $22.1 million from the exchange of the CBI Note[136] - Decrease in interest income of $5.8 million, from $7.8 million to $2.1 million, due to lower cash and cash equivalents and short-term investment balances[136] - Decrease in interest expense of $11.0 million, from $32.2 million to $21.1 million, primarily due to the reduction of debt balances[137] - Income tax expense increased to $6.2 million in fiscal 2025 Q1, compared to $2.0 million in fiscal 2024 Q1, driven by deferred income tax expense[138] - Net loss from continuing operations increased to $129.2 million in fiscal 2025 Q1, compared to $10.6 million in fiscal 2024 Q1, primarily due to changes in other income (expense)[139] - Adjusted EBITDA loss decreased to $5.3 million in fiscal 2025 Q1, compared to $23.0 million in fiscal 2024 Q1, driven by increased gross margin and decreased selling, general, and administrative expenses[141] Cash Flow and Debt Management - Cash and cash equivalents stood at $192.2 million, with short-term investments of $2.8 million as of June 30, 2024[142] - Established an ATM Program allowing the sale of up to US$250 million of common shares, with $46.3 million in gross proceeds from selling 4,747,064 common shares in Q1 fiscal 2025[142] - Net cash used in operating activities decreased to $51.8 million in Q2 2024 from $148.7 million in Q2 2023, primarily due to reduced working capital spending and lower cash interest payments[143] - Cash used in investing activities totaled $33.0 million in Q2 2024, compared to cash provided of $142.6 million in Q2 2023, driven by strategic investments in Acreage's debt and reduced short-term investment redemptions[143] - Cash provided by financing activities was $105.8 million in Q2 2024, compared to cash used of $133.1 million in Q2 2023, mainly due to proceeds from share sales and warrant exercises[147] - Free cash flow improved to an outflow of $55.7 million in Q2 2024 from $108.2 million in Q2 2023, reflecting reduced operating cash outflows[148] - Total debt outstanding decreased to $560.9 million as of June 30, 2024, from $597.2 million as of March 31, 2024, due to debt settlements and repayments[149] - The company repurchased $11.2 million of Credit Facility principal in Q1 2025, reducing total principal to $584.5 million as of June 30, 2024[149] - Strategic investments in other financial assets totaled $95.3 million in Q2 2024, primarily for the acquisition of Acreage's debt[143] - Purchases of property, plant, and equipment were $3.9 million in Q2 2024, focused on Canadian cultivation and production facility improvements[143] - Net redemptions of short-term investments decreased to $30.0 million in Q2 2024 from $72.2 million in Q2 2023, with $2.8 million remaining as of June 30, 2024[143] - The Credit Facility maturity was extended to December 18, 2026, with a mandatory $97.5 million prepayment required by December 31, 2024[151] - Supreme Cannabis issued $100.0 million in 6.0% senior unsecured convertible debentures on October 19, 2018, later amended to cancel $63.5 million of principal, increase the interest rate to 8%, extend the maturity date to September 10, 2025, and reduce the conversion price to $2.85[152] - Supreme Cannabis issued new senior unsecured non-convertible debentures (Accretion Debentures) on September 9, 2020, with a principal amount starting at $nil and accreting at 11.06% annually, reaching a final principal amount of $10.4 million by September 9, 2023[152] - The May 2024 Convertible Debenture was issued with an aggregate principal amount of $96.4 million, bearing interest at 7.50% per annum, and is convertible into Canopy Shares at $14.38 per share[154] - The May 2024 Investor delivered approximately $27.5 million in Supreme Debentures and Accretion Debentures and paid approximately US$50 million in exchange for the May 2024 Convertible Debenture and 3,350,430 May 2024 Investor Warrants[154] - The company's financial liabilities consist of long-term fixed-rate debt of $103,691 and variable-rate debt of $480,797 as of June 30, 2024[164] Regulatory and Legal Considerations - The company is monitoring the legalization of cannabis for medical or adult-use in jurisdictions outside of Canada and intends to participate in such markets if legalized[100] - The company is assessing the ongoing impact of developing provincial, state, territorial, and municipal regulations on the sale and distribution of cannabis[100] - The company is considering the resolution of litigation and other legal and regulatory proceedings, reviews, and investigations[100] - The 2024 Federal Budget Proposals increase the capital gains inclusion rate from one-half to two-thirds for corporations, trusts, and individuals on gains exceeding $250,000[117] Operational and Production Capabilities - The company operates two major cannabis cultivation facilities in Kincardine, Ontario, and Kelowna, British Columbia, with the Kincardine facility holding EU GMP certification for exporting medical cannabis to Europe and other global markets[103] - The company's licensed operational capacity in Canada includes advanced manufacturing capabilities for oil, softgel encapsulation, pre-rolled joints, and hash production, primarily at the Smiths Falls, Ontario facility[103] - The company offers a 20% discount on medical cannabis prices for eligible low-income patients through its income-tested compassionate pricing program[103] - The company's European medical cannabis business operates under EU GMP compliance, supplying pharmaceutical-grade products to medical markets in Europe and Australia[103] - The company restructured its financial reporting into four segments: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works, with the latter sold on December 18, 2023[105] - The company is focused on expanding production and manufacturing capabilities, with expectations for costs, timing, and receipt of necessary licenses[100] Goodwill and Impairment - The carrying value of goodwill associated with the Storz & Bickel reporting unit was $43,368 at June 30, 2024[158] - The company is required to perform its next annual goodwill impairment analysis on March 31, 2025, or earlier if an event occurs that would likely reduce the fair value of a reporting unit below its carrying amount[159] Off-Balance Sheet Arrangements - The company has no off-balance sheet arrangements that are reasonably likely to have a material effect on its financial condition[156]